The steroid-5-alpha-reductase, alpha polypeptide 2 (SRD5A2) gene plays a crucial role in androgen metabolism pathway in human prostate. It encodes SRD5A2 enzyme, which catalyses testosterone to dihydrotestosterone (DHT). DHT is the main active structure binding with androgen receptor (AR). After the activation of AR, it further regulates a series of target genes in androgen metabolism pathway. However, no clear consensus has been reached on the association between the SRD5A2 V89L, A49T and TA repeat polymorphisms and prostate cancer (PCa) risk. Thus, we performed a meta-analysis of 31 association studies with 14 726 PCa cases and 15 802 controls. We found no association between PCa and 89L compared with 89V allele [odds ratio (OR) 5 1.02, 95% confidence interval (CI) 0.98-1.06, P heterogeneity 5 0.44]. The 49T allele showed a significantly elevated effect on the high stage (Stages III-IV) of PCa risk both under the dominant genetic model (OR 5 2.13, 95% CI 1.44-3.15, P heterogeneity 5 0.65) and in the contrast T versus A allele (OR 5 2.06, 95% CI 1.41-3.02, P heterogeneity 5 0.69). There was a significantly decreased association between PCa and long TA repeat as compared versus short TA repeat (OR 5 0.86, 95% CI 0.74-1.00, P heterogeneity 5 0.79). No significant between-study heterogeneity was found in all subjects under four genetic models (dominant model, recessive model, allele comparison and homozygosity comparison) for these three polymorphisms, respectively, so the fixed effects model was used to pool the result. Our result indicated that carriers of 49T might improve the risk of PCa in higher stages (Stages III-IV), carriers of long TA repeat might decrease the risk of PCa and 89L may not be an important risk factor for PCa. However, due to the limited sample sizes, this meta-analysis did not achieve sufficiently conclusive results. Still more welldesigned studies should be performed to clarify the role of these three polymorphisms in the development of PCa.
Introduction
Prostate cancer (PCa) has become a public health problem in the last two decades (1) . It is the most common cancer and the second common cause of cancer mortality in American men (2) . Androgenic hormones have been reported to play a pivotal rule in androgen pathways and to be involved as initiators or promoters in prostate carcinogenesis. Therefore, it has been hypothesised that variation in genes involved in androgen biosynthesis and metabolism might be risk factors for PCa. There are two potent androgens in humans and other mammals, testosterone and DHT. DHT is converted from testosterone by steroid-5-alpha-reductase isozymes (3) . Up to date, two steroid-5-alpha-reductases have been identified. Although both of them are expressed in the human prostate, steroid-5-alpha-reductase, alpha polypeptide 2 (SRD5A2) is the predominant isozyme that is encoded by SRD5A2 gene. After the catalysis of this enzyme, the binding affinity of DHT to androgen receptor is five times higher than that of testosterone (4) . Increased level of DHT could affect the risk of PCa.
Polymorphisms V89L and A49T in SRD5A2 gene have been investigated extensively for decades (5) . A49T (a missense substitution of threonine for alanine at codon 49 due to a G to A transversion, rs9282858) substitution mutation increases steroid-5-alpha-reductase activity 5-fold in vitro compared to wild type gene (5) , while the V89L (a missense substitution of leucine for valine at codon 89 due to a G to C transversion, rs523349) substitution mutation results in an almost 30% reduction in enzyme activity both in vitro and in vivo when compared with wild type gene (6) . Thus, these two polymorphisms might alter the level and activity of DHT and consequently, the risk of PCa.
A (TA) dinucleotide repeat (located in the 3# untranslated region in exon 5) has also been studied in SRD5A2 gene. There are mainly three families that differ in the exact number of TA dinucleotide repeat, they are TA 0, TA 9 and TA 18, as well as some minor variation in the exact number of TA repeat (7) . It was hypothesised that these long alleles (TA 9 and TA 18, etc.) might be associated with an increased risk of PCa (8) .
However, molecular epidemiological studies have shown conflicting results concerning a potential role of the V89L, A49T and TA repeat polymorphisms in prostate carcinoma susceptibility. Considering the possible small effect size of these three polymorphisms to PCa and the relatively small sample size in each study, it is important to perform a quantitative synthesis of the evidence using rigorous methods. Therefore, the aim of this meta-analysis was to address the association of SRD5A2 V89L, A49T and TA repeat polymorphisms with risk of PCa.
Materials and methods

Identification and eligibility of relevant studies
To identify all articles that examined the association of SRD5A2 V89L and A49T and TA repeat polymorphisms with PCa, we conducted a literature search of PubMed database (from June 1993 to March 2010) using the following keywords and subject terms: 'SRD5A2', 'polymorphism' and 'prostate cancer'. References of retrieved articles were also screened. Abstracts, case reports, editorials and review articles were excluded. When an article reported results on different ethnicity subpopulations, each subpopulation was treated as a separate study. Studies included in the current meta-analysis had to meet all the following criteria: (i) use an unrelated case-control design, (ii) have available genotype frequency, (iii) genotype distribution of control population must be in Hardy-Weinberg equilibrium (HWE) and (iv) papers must be available in English. We included disease-free controls regardless of whether they had benign prostatic hyperplasia (BPH) or cellular atypia or prostatic intraepithelial neoplasia (PIN) or impotence. Studies of familial or hereditary cancer were excluded. For duplicate studies, the one recruiting larger samples was chosen.
Data extraction
Data were collected on the genotype of V89L, A49T and TA repeat polymorphisms, authors, year of publication, ethnicity of study population (categorised as Caucasian, Asian, African and Other), and characteristics of cases and controls were described. In subgroup analyses, data were extracted separately according to different descents whenever possible. 'Other' group (for example, Indian) included those populations which were difficult to be grouped into any of the three descents (Caucasian, Asian and African). Studies that did not provide specific genotyping data of ethnicity were also indicated as 'other' group.
Statistical analysis
We examined association between allele L of SRD5A2 V89L and PCa risk, as well as the recessive genetic model (LL versus VL þ VV), the dominant genetic model (LLþ VL versus VV) and the homozygote comparison model (LL versus VV). The same method was used to analyse the A49T and TA repeat polymorphisms. For the TA repeat polymorphism, we considered TA 9 and the very rare TA 18 and TA repeat with number above nine as the long allele versus the short allele TA 0 (9). Besides, we performed meta-analyses stratified by tumour grade, stage, and by ethnicity.
As case-control studies were involved, odds ratios (OR) corresponding to 95% confidence interval (CI) was used to measure the strength of association between the three polymorphisms and PCa, respectively. OR was calculated according to the method of Woolf (10) . A chi-square-based Q statistic test was performed to assess the between-study heterogeneity (11) . The between-study heterogeneity was considered significant for P value , 0.10. We conducted two models of meta-analysis for dichotomous results: the fixed effects model using the Mantel-Haenszel method and the random-effects model using the DerSimonian and Laird's method (12) . The fixed effects model assumes that studies are sampled from populations with the same effect size, making an adjustment to the study weights according to the within-study variance. A random-effects model considers the extent of variation and heterogeneity across studies and calculates study weights both from within-study and between-study variances. In the absence of between-study heterogeneity, the two methods provide identical results. However, random effects model is more appropriate when between-study heterogeneity is present. The significance of the pooled OR was determined by the Z test.
Publication bias was investigated by using a funnel plot, in which the standard error of log (OR) of each study was plotted against its OR. An asymmetry plot suggested possible publication bias. Funnel plot asymmetry was assessed by the method of Egger's linear regression test (13) . The significance of the intercept was determined by the t-test, and a P value , 0.05 was considered statistically significant. Hardy-Weinberg equilibrium was examined by the chi-square test for goodness of fit with a web program (http:// ihg.gsf.de/cgi-bin/hw/hwa1.pl). Analyses were conducted using the software Stata version 10.0 (College Station, TX, USA), Review Manager 4.2.8 (Oxford, UK). All the P values were two sided.
Results
Study inclusion
Through literature search and selection based on the inclusion criteria, we identified 33 eligible articles. Of the 33 articles, 4 pairs of studies were duplicate, respectively (derived from the same cohort): 1 pair of studies presented complementary data on V89L and A49T (14,15); 1 pair provided complementary data on V89L and TA repeat (9,16); 1 pair completely duplicate for V89L (17, 18) and 1 pair of studies completely duplicate for all the three polymorphisms (2, 19) . In the same pairs with complementary data, studies with more participants (18, 19) were included. Ultimately, 31 articles (55 studies) were used for meta-analysis (Table I) (9, 19, 29, (33) (34) (35) 43 ) (7 studies) studied TA repeat polymorphism (Table I) . Of all the eligible articles, 17 (14, 15, 18, (20) (21) (22) 24, (27) (28) (29) (30) (31) 34, 36, 38, 42, 43) confirmed PCa based on histological or pathological diagnosis and 10 articles (3, 9, 16, 19, 23, 26, 35, 37, 39, 41) selected PCa patients according to the review of medical records and pathology reports, whereas other 4 (25, 32, 33, 40) did not elucidate the diagnostic basis. Eight articles (18, 26, 27, 31, 36, (41) (42) (43) included BPH, cellular atypia, PIN and impotence patients as part of the controls. Twenty-two of 31 articles stated that age of subjects was matched between case and control populations. All studies used blood sample for genotyping.
Summary statistics
The allele frequencies were calculated for controls from the corresponding genotype distributions (Table II ). The 89V allele had a higher representation among controls of Africans (72.5%) than in controls of Caucasian descent (71.9%) or Asian descent (52.2%). The prevalence of the 49A allele was 97.2% in control subjects of Caucasians. Among controls, prevalence of TT homozygosity in Caucasians was only 0.05%. The prevalence of short TA repeat allele was 86.9% in controls of Caucasians. In all subjects, the prevalence of 89V, 49A and short TA repeat allele was 67.6%, 97.6%, and 87.6% in controls, respectively. (Table II) .
Quantitative synthesis V89L. We found no statistical significance in PCa risk associated with 89L allele under dominant model in all subjects (P 5 0.33, fixed effects OR 5 1.03, 95% CI 0.97-1.09, P heterogeneity 5 0.40) (Table III(a)) and in Caucasians (P 5 0.18, fixed effects OR 5 1.05, 95% CI 0.98-1.11, P heterogeneity 5 0.31) (Figure 1 ). In Asian subjects, there was no evidence that L allele associated with the risk of PCa under recessive model (P 5 0.93, random-effects OR 5 1.02, 95% CI 0.71-1.45, P heterogeneity 5 0.06) (Table III(a)). Significant between-study heterogeneity was only observed under recessive model in Asian subjects. Thus, the random effects model was used to pool the result. Not a single study influenced the pooled ORs and between-study heterogeneity as revealed by sensitivity analysis (data not shown). In all subjects and the analysis of every descent subgroup except Asians, we used fixed effects model to pool the result.
Four (16, 19, 24, 27 ) of 31 studies examined the association of 89L with the risk of grades of PCa according to the widely used Gleason system (44) (Table III(a)). The categorising of tumours with Gleason Score (GS) 7 into certain prognostic groups varied among the four studies. Two studies (16, 19) shared the same categorising method (low and intermediate, GS 0-6; high, GS 7-10); while the other two reports (24, 27) only recruited patients with intermediate (GS 5-7) and high grades (GS 8-10). We then divided these four studies into two groups: (16) and (19) as a group; (24) and (27) as another group. In the subgroup (intermediate, GS 5-7; high, GS 8-10) of high grade, no association could be observed under recessive genetic model (P 5 0.68, random-effects OR 5 0.85, 95% CI 0.40-1.80, P heterogeneity 5 0.05) (Table III(a)) and homozygote comparison (P 5 0.61, random-effects OR 5 0.81, 95% CI 0.36-1.84, P heterogeneity 5 0.05). Significant between-study heterogeneity was observed in this subgroup under these two genetic models, so the random effects model was used to pool the results. In summary, there was no association between 89L Some of the studies were marked as 'other' ethnic because the genotyping data were from different populations. V, V89L; A, A49T; T, TA repeat. DRE, digital rectal examination; PSA, prostate specific antigen; TRUS, transrectal ultrasound; AUA, american urological association. (15, 16, 19, 24, 27, 28) analysed the association of 89L with the risk of the stages of PCa (Table  III( a) ). As to stratification of PCa, there are two commonly used staging schemes. One is the American Joint Committee on Cancer (AJCC)-the International Union Against Cancer (UICC) Tumour Node Metastasis (TNM) system, which evaluates the size of tumour, the extent of involved lymph nodes and any metastasis (distant spread). The other one is Whitmore-Jewett system, which is similar to the TNM system, with approximately equivalent stages from Stage A to Stage D (45) . Patients were stratified into Stages I-II and Stages III-IV according to the TNM system in four studies (15, 19, 24, 28) , while patients were staged to Stages A-B and Stages C-D subgroups in accordance with the modified Whitmore-Jewett system in another two studies (16, 27) . When compared 89L versus 89V allele, no statistically significant association between 89L and different stages of PCa was found (Table  III( a) ). The fixed effects model was used to pool the result, as there was no significant between-study heterogeneity.
A49T. We found no significant effect on PCa risk for the T allele under dominant model in all subjects (P 5 0.13, fixed effects OR 5 1.14, 95% CI 0.96-1.35, P heterogeneity 5 0.52), as well as in Caucasian descent (P 5 0.16, fixed effects OR 5 1.14, 95% CI 0.95-1.37, P heterogeneity 5 0.33) (Figure 2) . No significant between-study heterogeneity was observed under dominant model in all subjects or in Caucasians (Table III(b)) . Thus, the fixed effects model was used to pool the result. Under other three genetic comparisons, the results of the pooled OR were also non-significant. Carrier of TT homozygosity Fig. 1 . Overall meta-analysis for the association between V89L polymorphism and PCa under dominant model in different kinds of ethnicities: Asians, Caucasians and Africans. The study is shown by a point estimate of the OR and the accompanying 95% CI under a random effects model. n indicates the total number of LL plus VL genotypes; N indicates the total number of individuals.
SRD5A2 polymorphisms genotype was not found in 'other' subgroup, thus the results of 'other' subjects under recessive model were not applicable (Table III(b)) .
Investigators in four studies (19, 24, 40, 42) presented information on cancer grade. However, because of various classification criteria among studies, no meaningful subgroup analysis of cancer grade was accessible. According to the TNM classification system, these four studies examined the association of 49T to the risk of different stages of PCa (Table III(b)) . Like V89L, patients were stratified into two subgroups: Stages I-II and Stages III-IV. There was a significantly elevated association between the 49T allele and Stages III-IV of PCa both under dominant genetic model (P 5 0.0001, fixed effects OR 5 2.13, 95% CI 1.44-3.15, P heterogeneity 5 0.65) (Figure 3a ) and in the contrast T versus A (P 5 0.0002, fixed effects OR 5 2.06, 95% CI 1.41-3.02, P heterogeneity 5 0.69) (Figure 3b) . Similarly, there was no carrier of TT homozygosity under different cancer stages, thus the results under recessive genetic model were not applicable (Table III( b) ).
TA repeat. In all subjects, there was a significantly decreased association between PCa risk and long TA repeat allele as compared with short TA repeat (P 5 0.04, fixed effects OR 5 0.86, 95% CI 0.74-1.00, P heterogeneity 5 0.79) (Table III(c)) . Reduced risk of PCa had also been shown in 'other' group under the dominant model (P 5 0.009, fixed effects OR 5 0.62, 95% CI 0.43-0.89, P heterogeneity 5 0.70) (Figure 4) , as well as in the contrast of long TA repeat versus short TA repeat (P 5 0.02, fixed effects OR 5 0.66, 95% CI 0.47-0.92, P heterogeneity 5 0.79) (Table III(c)). The 'other' group consisted of two studies: one is the study of Hsing et al. that reported Chinese subjects, while the other one is the study of Sobti et al. including Indian subjects. In the study of Hsing et al. (33) , about two-thirds of the cases were diagnosed as having advanced cancer (regional/remote stages), and most tumours were moderately or poorly differentiated. Similarly, in the report of Sobti et al. (43) , 127 of 157 cases were diagnosed as metastatic cancer. No statistically significant between-study heterogeneity was observed under dominant model in all subjects or Caucasian descent, so the fixed effects model was used to pool the result (Table III(c)) . Analysis stratified by cancer stage or grade could not be performed since little detailed information was available, and staging and grading criteria varied among studies.
Publication bias. The funnel plot was applied for comparison of 89L versus 89V in the OR analysis of SRD5A2 V89L, and Egger's test provided no evidence for funnel-plot asymmetry (t 5 À0.13, P 5 0.896) (Figure 5a) . Similarly, no publication biases were detected for A49T and TA repeat polymorphisms (t 5 À0.81, P 5 0.433) ( Figure 5b) ; (t 5 À0.64, P 5 0.551), respectively, (Figure 5c ).
Discussion
Due to the pivotal role of androgen and AR in the development of PCa, researchers have paid close attention to genetic association studies about genes involved in androgen In more than half of the studies eligible for our analysis, investigators reported results stratified according to potential measures of cancer stage and grade, so we performed metaanalysis for this subset. The most widely used grading system for PCa is the Gleason system (44). The GS is used to identify the differentiation extent of the tumour cells. The higher the grade, the more undifferentiated the tumour is. Generally, different GS were divided into three subset: low (GS 2-4), Patients with tumours of GS 7, although in the past considered to be intermediately differentiated, have recurrence rates that approach those of patients with high-grade tumours (51) . For V89L, we classified cases into two subgroups: low and intermediate (GS 0-6) and high (GS 7-10); intermediate (GS 5-7) and high grades (GS 8-10). We found no association between 89L and different grades of PCa.
There are two schemes commonly used to stage PCa. The most common is the AJCC-UICC TNM system, which evaluates the size of the tumour, the extent of involved lymph nodes and any metastasis (distant spread). The TNM system assigns tumours to four categories: Stage I, clinically unapparent tumour, not palpable nor visible by imaging; Stage II, tumour confined within the prostate; Stage III, tumour extends through the prostate capsule and Stage IV, tumour is fixed or invades adjacent structures other than seminal vesicles (52) . The other scheme, also used commonly, is the Whitmore-Jewett system, which is similar to the TNM system, with approximately equivalent stages from Stage A to Stage D (45) . Although the modified Whitmore-Jewett system was long favoured in North America, the AJCC-UICC system has gained general acceptance (53) . The TNM classification is a consensus between the UICC and the AJCC, with support from the Society of Urological Oncology (54) . In our meta-analysis, 89L showed no significant association with any stage of PCa (Table III(a)) .
For A49T, our result showed a significantly elevated association between 49T and Stages III-IV of PCa both in the contrast of T versus A and under dominant model (Figure 3) . It is acknowledged that AR signalling pathway plays a central role in the development of PCa, and androgen deprivation therapy is still the standard systemic treatment for PCa (1) . Unfortunately, the majority of patients treated with androgen deprivation therapies invariably progressed with a more aggressive form of PCa that has been termed androgenindependent prostate cancer (AIPC) (55, 56) . Researchers have found evidence for the potential mechanism of the progression: (i) alteration of the normal AR activity, (ii) changes in the expression of AR gene or co-regulators of AR and (iii) mutations of the AR gene that allow it to be constitutionally activated or to be activated by non-specific ligands, thus potentially leading to androgen independence (57). Thomas et al. (58) advanced that SRD5A2 inhibition might be an effective tool for the prevention and/or treatment of PCa. Makridakis et al. (5) reported A49T substitution increased steroid-5-alpha-reductase activity 5-fold in vitro. Montgomery et al. (59) found the concentration of androgen in AIPC tissues was 3.8-fold compared to that of the PCa tissues without androgen deprivation therapies, and the expression of SRD5A2 gene increased significantly in AIPC. The results above showed that after the treatment of androgen deprivation therapies, the PCa tended to progress to the high stage and for survival, the tumour cells might resist the decrease of serum androgen with increasing the local androgen level. Therefore, the tumour tissues would need more steroid-5-alpha-reductase to catalyse the testosterone. Because patients with 49T polymorphism are likely to have higher steroid-5-alphareductase activity than patients with 49A, so they will probably have a higher risk to develop high stage of PCa. Our metaanalysis indicated that 49T allele had a significant association with high stage of PCa.
Interestingly, in all eligible studies of this meta-analysis, we found no carriers of 49T allele identified among the native-Hawaiian cases in the study of Pearce et al. (40) and SRD5A2 polymorphisms among the Caucasian cases in the study of Forrest et al. (35) . The TT genotype presented even more rarely. Among 14 726 cases and 15 802 controls, only three cases and two controls of Caucasian descent had TT genotype. This phenomenon brought us to think about whether the TT genotype is capable of causing death. Up to date, no detailed research has been focused on this field, and more information about this genotype is needed in the future.
In conclusion, our meta-analysis found that V89L was not associated with PCa, TA repeat may have a protective effect on PCa risk and A49T was associated with high stage (Stages III-IV) of PCa. These results could have been partly distorted by inadequate statistical power and small sample sizes. Therefore, more studies or large case-control studies, especially studies stratified for cancer stage and grade are still needed to clarify the possible roles of SRD5A2 three polymorphisms in the development and progression of PCa.
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